Amy Raskopf

Chief Business Development Officer

Since joining Evofem in 2018, Amy has progressively advanced to senior leadership roles, culminating in her appointment as Chief Business Development Officer in 2024. In this capacity, she spearheaded Evofem’s acquisition of SOLOSEC® (secnidazole) 2g granules, an FDA-approved single-dose oral antibiotic for two common sexual health conditions.

In addition, to-date Amy has successfully negotiated two ex-U.S. commercial agreements that expand and diversify Evofem’s revenue stream. Our licensee for the Middle East plans to launch Phexxi® (lactic acid, citric acid, and bitartrate) and SOLOSEC in the first quarter of 2026 in the United Arab Emirates, followed by additional markets in the licensed Territory.

Amy continues to actively pursue growth opportunities to expand Evofem’s commercial offering and grow revenues in the U.S. and abroad. Her focus includes potential acquisitions or licensing of synergistic assets in women’s sexual and reproductive health, as well as partnerships to commercialize Evofem’s products in additional international markets.

With more than 25 years of experience in both public and private healthcare companies, Amy has dedicated her career to advancing products that can significantly improve patients’ lives. She holds a Bachelor of Arts from Smith College and Master of Fine Arts from Southern Methodist University.